Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis | Bentham Science
Frontiers | Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 3 (2021)
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
JCI Insight - Targeting the undruggable oncogenic KRAS: the dawn of hope
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - Ye Yuan, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, Wenwei Hu, 2021
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX | Scientific Reports
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020 | Published in healthbook TIMES Oncology Hematology
IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
Cells | Free Full-Text | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
Study reveals potential target for precision colorectal cancer treatment - Redox Medicine Society
Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers - ScienceDirect
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
RAS mutations: impact on treatment outcome | Colorectal Cancer
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
Can KRAS Positive Colorectal and Lung Cancer Finally be Targeted? - CancerConnect
